Share Price:

APNASPENAspen Pharmacare Hldgs17034122 (0.72%)
Our Response to Covid
Country Sites

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Regional Overviews

Aspen in Americas

The Americas region is the second largest in terms of sales teams. It features well-recognised domestic and global brands, particularly in the Latin America and Brazil
markets, which drive the majority of sales in these territories. Brazil also has a manufacturing facility which specialises in finished dose form (“FDF”).

Key Countries

Argentina
Brazil
Canada
Chile
Colombia
Mexico

Overview

Learn More
Brand Therapeutic category
Diprivan

General anaesthetic
Durateston

Testosterone replacement therapy
Lyrica

Anti-epileptic drugs
Meticorten

Corticosteroid
Magnesia Bisurada

Antacid
Ovestin

Estrogen hormone replacement
10
Products
Launched

(2023: 19)

0
Product
Recalls

(2023: 2)

0 %
Average Staff
Turnover

(2023: 27%)

0
Work-related
Facilities

(2023: Nil)

100
Sales
Representatives

(2023: 228)

610
Permanent
Employees

(June 2024)

600
Permanent
Employees

(June 2023)

5
Products
Launched

(2022: 20)

Product
Recalls

(2022: 1)

5 %
Average Staff
Turnover

(2022: 22)

Work-related
Facilities

(2022: Nil)

135
Sales
Representatives

(2022: 235)

250
Permanent
Employees

(June 2022: 714)

Revenue 2024
R’million		 2023 (CER)
R’million		 Change
%

Commercial Pharmaceuticals

6 677

5 564

20

Prescription

2 832

1 990

42

Injectables

2 395

2 133

12

Over the counter

1 450

1 441

1

Manufacturing

Finished dose form

34

20

70
Total

6 711

5 584

20

Note: Commercial Pharmaceuticals’ revenue is by customer geography.

Contribution to Group revenue (%)
  • Rest of Group 85
  • Americas 15
Revenue by segment (%)
  • Injectables36
  • Prescription 25
  • Over the counter 22
Contribution to Group revenue (%)
  • Rest of Group 88
  • Americas 12
Revenue by segment (%)
  • Regional Brands 68
  • Sterile Focus Brands 32
  • Latin America is expected to grow 1,9% CAGR between 2024 and 2028
Source: IQVIA Institute, December 2023.

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.